Prospective real-world study shows tildrakizumab enhances disease severity and quality of life in patients with psoriasis, suggesting the importance of patient-reported outcomes.
Tildrakizumab improves both objective disease severity and quality of life at week 16. PASI strongly correlates with PROM improvements early in treatment, but correlations diminish over time, suggesting possible adaptation once skin clearance is sustained. PROMs should be integrated into long-term management to capture patient-centered benefits beyond skin clearance.
No takes yet. Share an insight, caveat, or question.
Facheris et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: